Drug Trial Radar · NCT03383042
Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of JP-1366 Oral Administration in Healthy Male Subjects
Last checked: Nov 19, 2026Latest source record: Apr 22, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
115
Actual
Start
Dec 22, 2017
Primary completion
Nov 23, 2018
Study completion Apr 5, 2019
Sponsor
- Lead sponsor
- Jeil Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 26, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 19 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Clinical trial to investigate the safety, tolerability and pharmacokinetics and pharmacodynamics of JP-1366 oral administration in healthy male subjects
Conditions
- Anti-Ulcer Agents
Interventions
Cohort 1 (JP-1366 A mg)Drug
Drug: JP-1366 A mg or JP-1366 Placebo or Esomeprazole 40 mg
Cohort 2 (JP-1366 B mg)Drug
Drug: JP-1366 B mg or JP-1366 Placebo or Esomeprazole 40 mg
Cohort 3 (JP-1366 C mg)Drug
Drug: JP-1366 C mg or JP-1366 Placebo or Esomeprazole 40 mg
Cohort 4 (JP-1366 D mg)Drug
Drug: JP-1366 D mg or JP-1366 Placebo or Esomeprazole 40 mg
Cohort 5 (JP-1366 E mg)Drug
Drug: JP-1366 E mg or JP-1366 Placebo or Esomeprazole 40 mg
Cohort 6 (JP-1366 F mg)Drug
Drug: JP-1366 F mg or JP-1366 Placebo or Esomeprazole 40 mg
Cohort 7 (JP-1366 G mg)Drug
Drug: JP-1366 G mg or JP-1366 Placebo or Esomeprazole 40 mg
Cohort 8 (JP-1366 H mg)Drug
Drug: JP-1366 H mg or JP-1366 Placebo or Esomeprazole 40 mg
Cohort 9 (JP-1366 I mg)Drug
Drug: JP-1366 I mg or JP-1366 Placebo or Esomeprazole 40 mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- CmaxTime frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hours post-dose
- AUClastTime frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hours post-dose
- AUCinfTime frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hours post-dose
- tmaxTime frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hours post-dose
- t1/2Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hours post-dose
- Cmax,ssTime frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24h post-dose, Day 3-6, pre-dose, Day 7 pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hour post-dose
- Cmin,ssTime frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24h post-dose, Day 3-6, pre-dose, Day 7 pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hour post-dose
- Cav,ssTime frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24h post-dose, Day 3-6, pre-dose, Day 7 pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hour post-dose
- AUCτTime frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24h post-dose, Day 3-6, pre-dose, Day 7 pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hour post-dose
- tmax,ssTime frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24h post-dose, Day 3-6, pre-dose, Day 7 pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hour post-dose
- t1/2Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24h post-dose, Day 3-6, pre-dose, Day 7 pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24 and 48 hour post-dose
- Percentage of total time that the intragastric pH was above 4Time frame: 0-24 hours(Day -1), 0-24 hours(Day 1)
- Percentage of total time that the intragastric pH was above 4Time frame: 0-24 hours (Day -1), 0-24 hours (Day 1), 0-24 hours (Day 7)
- Serum gastrin concentrationTime frame: Pre-dose, 2, 4, 6, 8, 12h post-dose, Day 1 pre-dose, 2, 4, 6, 8, 12, 24, 48h post-dose
- Serum gastrin concentrationTime frame: Pre-dose, 2, 4, 6, 8, 12h post-dose, Day 1 pre-dose, 2, 4, 6, 8, 12, 24h post-dose, Day 4 pre-dose, Day 6 pre-dose, Day 7 pre-dose, 2, 4, 6, 8, 12, 24, 48h post-dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Seoul National University Hospital(SNUH)
Seoul, Jongno-Gu, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.